Metabasis Therapeutics, Inc. (Nasdaq: MBRX), a biopharmaceutical company focused on innovative therapies for metabolic diseases including hyperlipidemia and diabetes, today announced that it will hold a conference call to discuss the Company’s first quarter financial results.
Mark Erion, Ph.D., president, chief executive officer and chief scientific officer, Tran Nguyen, M.B.A., vice president and chief financial officer, and Barry Gumbiner, M.D., vice president of clinical development and chief medical officer, will host the call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Friday, May 15, 2009. A press release for the first quarter financial results will be released after market close on May 14th.
To participate in the live call by telephone, please dial 866-510-0710 from the U.S. or 617-597-5378 for international callers. Please specify to the operator “Metabasis” when asked for a passcode. In addition, the live conference call is being webcast and can be accessed on the Metabasis website at www.mbasis.com, under the Investors section, and will be archived there for 30 days following the call. Please connect to the Metabasis website several minutes prior to the start of the call to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis is a biopharmaceutical company using its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways to develop novel therapies to treat metabolic and other diseases. The Company has established a broad pipeline of product candidates and advanced discovery programs targeting large markets with significant unmet needs. Metabasis' core area of focus is on the discovery and development of drug candidates to treat metabolic diseases including hyperlipidemia and diabetes. Although not a core focus of the Company, Metabasis has also discovered and developed drug candidates for the treatment of liver diseases such as hepatitis and primary liver cancer, which it now intends to license or partner. All product candidates were developed internally using proprietary technologies and know how.
Contacts:
Metabasis Therapeutics, Inc.
Investor Relations & Corporate
Communications
858-622-2223
